Peripheral T-Cell Lymphoma Market Report 2026

The peripheral t-cell lymphoma market size has grown strongly in recent years. It will grow from $0.62 billion in 2025 to $0.66 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to limited availability of targeted therapies, reliance on chemotherapy regimens, high disease aggressiveness, late-stage diagnosis, inadequate patient monitoring infrastructure.

The peripheral t-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $0.81 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to advancements in immunotherapy and targeted therapy, increasing adoption of stem cell therapy, growing use of monoclonal antibodies and hdac inhibitors, rising availability of injectable and oral formulations, expansion of specialty clinics and research institutes. Major trends in the forecast period include increasing adoption of ai-based diagnostic and prognostic tools, rising application of genomics and precision medicine in ptcl treatment, growing use of big data analytics and cloud platforms for clinical decision support, increasing integration of industry 4.0 technologies in ptcl drug development, rising deployment of iot-enabled patient monitoring systems.

The high incidence of lymphoma is expected to support the growth of the peripheral T-cell lymphoma market in the coming years. Lymphoma is a type of cancer that originates in the lymphatic system, which plays a vital role in the body’s immune defense. The increasing occurrence of lymphoma is linked to factors such as genetic susceptibility, environmental exposure, viral infections including Epstein-Barr virus, immunodeficiency disorders, and lifestyle factors such as smoking and obesity. Peripheral T-cell lymphoma (PTCL) contributes to the overall lymphoma burden by arising from mature T-cells, resulting in aggressive disease characteristics, immune system disruption, and lower responsiveness to treatment compared with other lymphoma subtypes. For instance, according to the American Cancer Society Facts and Figures, a US-based professional organization, the estimated number of new non-Hodgkin lymphoma cases was 80,550 in 2023 and remained at 80,550 in 2024. Therefore, the high incidence of lymphoma is driving the growth of the peripheral T-cell lymphoma market.

Major companies operating in the peripheral T-cell lymphoma market are emphasizing the development of innovative products, such as dihydrofolate reductase inhibitors, to improve treatment effectiveness and patient outcomes. A dihydrofolate reductase inhibitor is a class of drugs that inhibits the activity of the dihydrofolate reductase enzyme, which is essential for DNA synthesis and cellular replication. For example, in December 2024, Fresenius Kabi AG, a Germany-based pharmaceutical company, launched Pralatrexate Injection, a generic version of Folotyn, for the treatment of relapsed or refractory peripheral T-cell lymphoma. This introduction broadens the company’s oncology portfolio by offering clinicians and patients a high-quality and cost-effective treatment alternative. The injection is available in 20 mg/1 mL and 40 mg/2 mL single-dose vials and received accelerated approval based on overall response rate, with continued approval dependent on confirmatory clinical trials.

In August 2024, Citius Pharmaceuticals Inc., a US-based pharmaceutical company specializing in treatments for relapsed or refractory cutaneous T-cell lymphoma (CTCL), merged with TenX Keane Acquisition to form Citius Oncology Inc. Through this merger, Citius Oncology Inc. aims to operate as a dedicated oncology-focused company, supporting the commercialization of Lymphir and strengthening its oncology development pipeline. TenX Keane Acquisition Corp. is a US-based company established to raise capital through an initial public offering with the objective of acquiring or merging with an existing business.

Major companies operating in the peripheral t-cell lymphoma market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Company Limited, BeiGene Ltd., Daiichi Sankyo Company Limited, Zymeworks Inc., Genor Biopharma Co. Ltd., Kura Oncology Inc., Spectrum Pharmaceuticals Inc., Verastem Inc., Astellas Pharma Inc., Autolus Therapeutics plc, Seagen Inc., Amgen Inc., Roche Holding AG, Gilead Sciences Inc.

North America was the largest region in the peripheral T-cell lymphoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peripheral t-cell lymphoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peripheral t-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the peripheral t-cell lymphoma market by increasing the costs of imported chemotherapy drugs, targeted therapies, and advanced diagnostic equipment, impacting hospitals, specialty clinics, and research institutes, especially in North America and Europe. While higher costs have slowed adoption in some regions, they have also encouraged local manufacturing, strategic sourcing, and development of cost-efficient treatment options, potentially accelerating innovation in immunotherapy and targeted drug classes.

The peripheral t-cell lymphoma market research report is one of a series of new reports that provides peripheral t-cell lymphoma market statistics, including peripheral t-cell lymphoma industry global market size, regional shares, competitors with a peripheral t-cell lymphoma market share, detailed peripheral t-cell lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral t-cell lymphoma industry. This peripheral t-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peripheral T-cell lymphoma (PTCL) is a group of aggressive non-Hodgkin lymphomas that arise from mature T-cells, which are white blood cells that play a critical role in immune function. PTCL can involve lymph nodes, the spleen, bone marrow, liver, and other organs. Common symptoms include enlarged lymph nodes, fever, night sweats, unexplained weight loss, skin rashes, and ongoing fatigue.

The major types of peripheral T-cell lymphoma include peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia or lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma, and other forms. PTCL-NOS refers to a malignancy originating from mature T-cells that does not fall into other defined subtypes. Treatment options include chemotherapy, targeted therapy, immunotherapy, stem cell therapy, and radiation therapy. The drugs used are categorized into histone deacetylase (HDAC) inhibitors, monoclonal antibodies, alkylating agents, antimetabolites, and other drug classes. These therapies are delivered through different routes, including oral and injectable, and are utilized by end users such as hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The peripheral T-cell lymphoma market consists of revenues earned by entities by providing services such as diagnosis and screening services, treatment services, hospital and specialty care services, clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral T-cell lymphoma market also includes sales of corticosteroids, anthracyclines, vinca alkaloids, and topoisomerase inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.